Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
89.17 CHF | -0.92% | +4.22% | +5.03% |
08:14am | NOVARTIS AG : Receives a Buy rating from Jefferies | ZD |
Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 4.02 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.03% | 201B | B- | ||
+24.35% | 653B | C+ | ||
+25.68% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+12.83% | 233B | B+ | ||
-9.98% | 193B | A+ | ||
-6.47% | 144B | C+ | ||
-12.26% | 143B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- Ratings Novartis AG